Immunological synapse formation

Across TCGA cell cohorts, RNA activity of the Immunological synapse formation pathway is significantly associated with the drug response of multiple features, with the BLOOD_Leukemia cohort showing a particularly strong set of associations.

The most reproducible pathway-associated features across cancer lineages are Alisertib, Crizotinib, and BI-2536, each associated with the pathway in up to 3 cancer types. Since the analysis shows associations rather than directional relationships, both pathway-to-partner and partner-to-pathway views are reported.

Each partner is linked to its corresponding Q-omics profile. The box plot shows the strongest association, Alisertib grouped by Immunological synapse formation-low versus -high activity in BLOOD_Leukemia.

Pathway-associated features by consensus

Ranked by combined sampling and lineage consensus. X-score (pathway→partner) and Y-score (partner→pathway) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner feature	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
BLOOD_Leukemia	Alisertib →	+0.989	+0.136	.020	.008	3	2
BLOOD_Leukemia	Crizotinib →	+0.635	+0.168	.023	.016	3	2
OESOPHAGUS	BI-2536 →	+1.509	+0.370	.007	.027	3	2
BLOOD_Leukemia	AZD6094 →	+0.399	+0.207	<.001	.004	3	2
BLOOD_Leukemia	Ispinesib Mesylate →	+1.094	+0.150	.005	.012	2	3
BLOOD_Leukemia	KIN001-042 →	+0.389	+0.146	.038	.038	3	2

Each partner links to its Q-omics profile. Showing the 6 strongest associations by consensus.

Alisertib by Immunological synapse formation activity — BLOOD_Leukemia

Explore this box plot interactively →